{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:58:52Z","timestamp":1791374332465,"version":"4.3.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacl.2025.09.028","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:13:05Z","timestamp":1759302785000},"page":"210-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breakthrough LDL-C reduction in a patient with autosomal recessive homozygous familial hypercholesterolemia: Efficacy of evinacumab after LDL-apheresis discontinuation"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-1308","authenticated-orcid":false,"given":"Pablo","family":"Gonz\u00e1lez-Bustos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-7366","authenticated-orcid":false,"given":"Francisco","family":"Fuentes-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2982-2716","authenticated-orcid":false,"given":"Javier","family":"Delgado-Lista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ojeda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Diego","family":"Mediavilla-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.09.028_bib0001","article-title":"Homozygous familial hypercholesterolemia in Spain. Data from registry of the Spanish Atherosclerosis Society","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"10421","key":"10.1016\/j.jacl.2025.09.028_bib0002","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(23)01842-1","article-title":"Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study","volume":"403","author":"Dharmayat","year":"2024","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jacl.2025.09.028_bib0003","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.09.028_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.11.004","article-title":"High burden of disease in patients with homozygous familial hypercholesterolemia despite recent advances in therapies and updated guidelines: a real-world study","author":"Gu","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.028_bib0005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamapediatrics.2023.6477","article-title":"Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"178","author":"Santos","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"5","key":"10.1016\/j.jacl.2025.09.028_bib0006","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","volume":"18","author":"Stefanutti","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.09.028_bib0007","doi-asserted-by":"crossref","DOI":"10.1515\/jpem-2024-0505","article-title":"Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia","author":"Stirnkorb","year":"2025","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.jacl.2025.09.028_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100648","article-title":"The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC Adv"},{"issue":"9","key":"10.1016\/j.jacl.2025.09.028_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100646","article-title":"Evinacumab therapy for homozygous familial hypercholesterolemia: driving lipoprotein clearance via the road less taken","volume":"2","author":"Toth","year":"2023","journal-title":"JACC Adv"},{"issue":"27","key":"10.1016\/j.jacl.2025.09.028_bib0010","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/eurheartj\/ehae321","article-title":"ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab","volume":"45","author":"Watts","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.09.028_bib0011","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.57187\/s.4024","article-title":"Evinacumab for the treatment of homozygous familial hypercholesterolaemia: first patient case report in Switzerland","volume":"155","author":"Corpataux","year":"2025","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"10.1016\/j.jacl.2025.09.028_bib0012","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1515\/jpem-2024-0506","article-title":"Dramatic response to evinacumab in a North Indian girl with homozygous familial hypercholesterolemia","volume":"38","author":"Arora","year":"2025","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jacl.2025.09.028_bib0013","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurjpc\/zwae036","article-title":"Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry","volume":"31","author":"D'Erasmo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2025.09.028_bib0014","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/ATVBAHA.123.320609","article-title":"Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia","volume":"44","author":"B\u00e9liard","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.jacl.2025.09.028_bib0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jcmg.2024.05.005","article-title":"Decreased LDL-cholesterol exposure following ANGPTL3 inhibition reduces coronary plaque development in homozygous familial hypercholesterolemia","volume":"17","author":"Schonck","year":"2024","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:47:59Z","timestamp":1791373679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1933287425004155"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.09.028","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breakthrough LDL-C reduction in a patient with autosomal recessive homozygous familial hypercholesterolemia: Efficacy of evinacumab after LDL-apheresis discontinuation","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}